Cellares vs Genentech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) for cell therapy, automating end-to-end CAR-T and cell therapy production; raised $257M Series D in 2026 led by BlackRock and Eclipse;
About
Cellares is a clinical-stage biotech and contract manufacturing company founded in 2019 by Fabian Gerlinghaus, James Cha, and Yi Zhao, headquartered in South San Francisco, California. The company has built the world''s first fully automated, integrated cell therapy manufacturing platform — the Cell Shuttle — which automates the entire end-to-end process of manufacturing patient-specific T-cell therapies (including CAR-T cells) in a single closed system. Traditional cell therapy manufacturing is highly manual, requiring highly trained technicians, specialized cleanroom infrastructure, and weeks of labor-intensive processing. Cellares replaces this with industrial-scale automation, compressing production timelines and dramatically reducing the cost and variability of cell therapy manufacturing.
Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.
About
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.